Close



Mar 13, 2024 08:05AM
Feb 12, 2024 08:05AM
Feb 12, 2024 08:05AM
Feb 6, 2024 05:52AM
Feb 5, 2024 06:01PM
Nov 1, 2023 04:01PM
Aug 8, 2023 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
May 22, 2023 08:05AM
May 22, 2023 08:05AM
Apr 27, 2023 05:17AM
Apr 26, 2023 05:28PM
Feb 22, 2023 04:01PM
Feb 22, 2023 03:02PM
Feb 22, 2023 03:01PM Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
Nov 3, 2022 04:01PM
Oct 12, 2022 04:17AM
Oct 12, 2022 03:01AM
Aug 30, 2022 06:01AM
Aug 30, 2022 06:00AM
May 5, 2022 04:01PM
May 3, 2022 09:55AM Sangamo BioSciences (SGMO) Partner Pfizer Announced Hemophilia-A Clinical Hold Lifted, 'A Clear Positive for SGMO' - RBC
May 3, 2022 09:54AM
Feb 24, 2022 04:01PM
Feb 8, 2022 05:35AM
Feb 7, 2022 06:00PM
Jan 6, 2022 08:07AM
Jan 6, 2022 08:00AM
Dec 13, 2021 05:08AM Sangamo Therapeutics (SGMO) Reports Positive Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data
Dec 13, 2021 05:04AM
Dec 12, 2021 04:30PM
Dec 12, 2021 09:00AM
Nov 4, 2021 09:05AM
Nov 4, 2021 08:05AM
Nov 4, 2021 08:00AM
May 4, 2021 05:24PM Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c, Revenues Beat
May 4, 2021 04:01PM
Dec 7, 2020 07:01AM
Dec 7, 2020 07:00AM
Oct 7, 2020 06:48AM
Oct 7, 2020 06:45AM
Aug 19, 2020 01:02PM
Aug 19, 2020 09:26AM Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)
Aug 19, 2020 09:13AM
Jul 30, 2020 09:28AM
Jun 18, 2020 09:05AM
Jun 18, 2020 09:00AM
Jun 18, 2020 09:00AM
Feb 28, 2020 09:27AM
Dec 9, 2019 06:49AM Sangamo Therapeutics (SGMO) Reports Preilm. Results from 1st Three Patients in Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-Edited Cell Therapy in Beta Thalassemia
Dec 9, 2019 06:45AM

251,770 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All